
Reshaping Hypertension™
with the MobiusHD® System
Now enrolling in the CALM-2 clinical study
for patients with poorly controlled hypertension
CAUTION: investigational device. Limited by United States law to investigational use.

Hypertension impacts 1 billion people worldwide and the clinical consequences are devastating1,2,3
When your blood pressure is high:





Have high blood pressure

of people with high blood pressure have their condition under control

Hear from Patients and Physicians

EVBA: EndoVascular Baroreflex Amplification




AMPLIFY
Reshaping of carotid sinus amplifies baroreceptor signaling to the brain

REDUCE
Significant blood pressure reduction demonstrated in multiple clinical studies4

LONG LASTING
Durable safety and efficacy at two-years4

NON-SURGICAL
Minimally invasive access using endovascular techniques

Clinical Trials
-
CALM-FIM
CALM-FIM was a prospective, first-in-human, open-label study done at six sites in Europe. The MobiusHD system was studied in patients with an office systolic blood pressure ≥160 mmHg despite taking at least three antihypertensive agents, including a diuretic.
Results showed a significant decrease in mean ambulatory blood pressure in 73% of patients at 24 hours and blood pressure reduction of 21/12 mmHg at six months, as compared to baseline4. -
CALM-2
The MobiusHD System is being studied in the CALM-2 clinical trial in patients with resistant hypertension who remain uncontrolled despite pharmacologic treatment with maximum tolerated, guideline-directed anti-hypertensive pharmacologic therapy.
The CALM-2 clinical trial is currently enrolling at select medical centers in the United States and Europe. For more information visit www.calm2study.com
See if you qualify

About Vascular Dynamics
Vascular Dynamics Inc. is pioneering endovascular baroreflex amplification (EVBA) to advance the treatment of hypertension to bring a better quality of life to patients who are resistant to conventional treatments.
The
MobiusHD System targets the natural baroreceptor response in the carotid sinus with a minimally invasive procedure and is designed to stimulate vasodilation, reduce heart rate and modulate kidney response, thereby decreasing
blood pressure.
The MobiusHD system has received a CE mark and has been accepted to participate in the FDA’s Expedited Access Pathway (EAP) program. The MobiusHD System is investigational in the United States.
CAUTION: investigational device. Limited by United States law to investigational use.
Leadership
-
Management
-
Board of Directors
Press Releases
Vascular Dynamics Names Prof. Martin Rothman Chief Medical Officer
Jan 23, 2019
Vascular Dynamics Announces Initial Enrollment in Rigorously Designed Hypertension Trial
Sept 4, 2018
Vascular Dynamics Appoints Ed Roschak CEO
Dec 4, 2017
Vascular Dynamics Interim Data on MobiusHD Presented at TCT Conference Shows Significant Reductions in Ambulatory Systolic Blood Pressure At Six Months
Oct 30, 2017
Vascular Dynamics Announces FDA Approval to Initiate CALM 2 Trial for MobiusHD® System for the Treatment of Resistant Hypertension
Sep 15, 2017
Data Published in The Lancet Shows Positive Results at Primary Endpoint in the Treatment of Resistant Hypertension with MobiusHD Device
Sep 1, 2017

Contact
Address:
2134 Old Middlefield Way, Suite J
Mountain View, California 94043 USA
P: +1.650.963.9370
E: info@vasculardynamics.com
©2018 Vascular Dynamics, Inc. All rights reserved. | Reshaping Hypertension is a trademark of Vascular Dynamics, Inc. MobiusHD is a registered trademark of Vascular Dynamics, Inc.